Congress moves to tax vaping and close tobacco loopholes
S. 819 — End Tobacco Loopholes Act · Filed by Richard Durbin (D-IL) · 7 cosponsors · Introduced Mar 3, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill significantly increases federal excise taxes on all tobacco products and newly imposes a tax on extracted nicotine used in vaping products. It harmonizes tax rates across cigarettes, cigars, smokeless tobacco, roll-your-own tobacco, and pipe tobacco—closing what sponsors call "loopholes" where some products faced lower taxes than others. The bill also imposes a one-time "floor stocks" tax on inventory held at enactment and includes automatic annual inflation adjustments to all tobacco tax rates going forward. Beneficiaries are the federal government (revenue) and public-health advocates; primary costs fall on tobacco manufacturers, distributors, retailers, and consumers.
Why we flagged it
The bill's core function is to increase and equalize federal excise taxes across all tobacco product categories (cigarettes, cigars, smokeless, roll-your-own, pipe tobacco, and newly taxed nicotine for vaping). It is fundamentally a revenue and public-health measure, not a commemorative or vanity bill.
What the text implies
- The new tax on extracted/concentrated nicotine (at $49.56 per 1,810 mg) may significantly increase costs for vaping manufacturers and e-cigarette producers, potentially shifting consumer behavior toward traditional cigarettes if vaping becomes unaffordable relative to taxed cigarettes.
- Floor stocks tax provisions impose a retroactive tax on inventory held at the time of enactment, creating a one-time compliance burden and potential cash-flow shock for distributors and retailers holding large inventories.
The full analysis lists 5 implications of this text.
Who stands to gain
U.S. federal government (revenue increase); State governments (if revenue-sharing mechanisms exist); Pharmaceutical companies producing FDA-approved nicotine replacement therapies